Zacks: IMMURON LTD/S (NASDAQ:IMRN) Receives Consensus Rating of “Strong Buy” from Analysts

IMMURON LTD/S (NASDAQ:IMRN) has been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.

Analysts have set a twelve-month consensus price objective of $20.00 for the company, according to Zacks. Zacks has also assigned IMMURON LTD/S an industry rank of 51 out of 256 based on the ratings given to its competitors.

IMMURON LTD/S stock traded down $0.55 during midday trading on Tuesday, reaching $3.05. The stock had a trading volume of 77,135 shares, compared to its average volume of 594,640. IMMURON LTD/S has a 12 month low of $2.38 and a 12 month high of $14.29. The business has a 50-day moving average of $3.14.

About IMMURON LTD/S

Immuron Limited, a biopharmaceutical company, focuses on the research and development of immunomodulatory polyclonal antibodies for the treatment and prevention of various diseases through its oral immunoglobulins platform in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments.

Read More: What do investors mean by earnings per share?

Get a free copy of the Zacks research report on IMMURON LTD/S (IMRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for IMMURON LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMMURON LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.